bepotastine

REMS

Contraindicated in:

Use Cautiously in:

Contact lens use ;
OB: Use during pregnancy potential maternal benefit justifies the potential risk to fetus;
Lactation: Use cautiously during breastfeeding;
Pedi: Safe and effective use in children <2 yr has not been established.

EENT: nasopharyngitis

GI: taste in mouth following instillation

Neuro: headache

Drug-drug:

Bepreve

Acts as a histamine H₁ receptor antagonist; also inhibits the release of histamine from mast cells; does not bind to or inactivate histamine.

Therapeutic effects:

Therapeutic Classification: ocular agents

Pharmacologic Classification: antihistamines

Absorption: Some systemic absorption follows ophthalmic administration.

Distribution: Unknown.

Metabolism/Excretion: Minimally metabolized by the liver; 75–90% excreted unchanged in urine.

Half-Life: Uknown.

(antihistaminic activity)

ROUTE	ONSET	PEAK	DURATION
ophth	within 15 min	1–2 hr‡	12 hr

‡blood levels.

Instruct patient to instill bepotastine drops as directed. Do not touch dropper to eye or to any surface.
Advise patient to remove contact lens prior to instillation. Do not use bepotastine for treatment of irritation related to contact lens. Do not wear contact lens if eyes are red. Contact lens may be reinserted 10 min following instillation.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

be-poe-TASS-teen

NDC Code

42672- UBE Corporation
- 42672-0100-
  - 42672-0100-1- 2 BAG in 1 DRUM (42672-0100-1) / 15 kg in 1 BAG